The FORSVALL NEEDLE is expected to significantly increase safety during diagnose of prostate cancer and other diseases by reducing the risk of getting sepsis/infection after a biopsy. The estimated annual savings due to infection reduction when using our needles in over 200M€ in emergency cost for prostate cancer diagnosis alone.
On the basis of the existing patented technology of Xaga Surgical’s biopsy needle, our company is in the perfect position to exploit the market opportunity for a safe, cheap and easy-to-use biopsy needle that aims to reduce the risk of infection – a task no competitor has been able to succeed with.